Xencor Reports Second Quarter 2021 Financial Results August 4, 2021 -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--(BUSINESS WIRE)--Aug. 4, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a review of recent business and portfolio highlights. "Xenco ...

Xencor, Inc. (NASDAQ:XNCR) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and Investor Relations Bassil Dahiyat - President and Chief Executive Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial Officer Allen Yang - Chief Medical Officer Conference Call Participants Ted Tenthoff - Piper Sandler Jonathan Chang - SVB Leerink Peter Lawson - Barclays Arlinda Lee - Canaccord Kaveri Pohlman - BTIG Xinyue Lu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36182 Xencor, Inc. (Exact name of registrant as specified in its charter) Delaware 20-162250 ...

| --- | --- | --- | --- | --- | |-------|----------------------------------|-------|-------|-------| | | | | | | | | Proteins by Design | ® | | | | | Antibody & Cytokine Therapeutics | | | | Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's deve ...

Xencor, Inc. (NASDAQ:XNCR) Q1 2021 Results Conference Call May 5, 2021 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Sandler Mara Goldstein - Mizuho Securities Peter Lawson - Barclays Li Wang Watsek - Cantor Etzer Darout - Guggenheim Tom Shrader - BTIG Zhiqiang Sh ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36182 Xencor, Inc. (Exact name of registrant as specified in its charter) Delaware 20-16225 ...

Xencor Inc (NASDAQ:XNCR) Q4 2020 Earnings Conference Call February 23, 2021 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Sandler Mara Goldstein - Mizuho Securities Gregory Renza - RBC Capital Markets Alethia Young - Cantor Fitzgerald Jonathan Chang - SVB Leerink ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation or Or ...

Xencor Inc (NASDAQ:XNCR) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Jonathan Chang - SVB Leerink Kaveri Pohlman - BTIG Etzer Darout - Guggenheim Securities Gabriel Fung - Mizuho Securities Arlinda Lee - Canaccord Zhiqiang Shu - Berenberg Operato ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36182 Xencor, Inc. (Exact name of registrant as specified in its charter) Delaware 20-1 ...